Sagimet Biosciences Inc.

SGMT · Nasdaq · SIC 2834: Pharmaceutical Preparations
63
SEC Filings

Business Summary

PART I Overview We are a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Our lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Our ...

Next Earnings

Q2 FY2026 — expected 2026-08-15

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionSGMTdiscussed_in_filing Artificial Intelligence
topic_mentionSGMTdiscussed_in_filing Cybersecurity
topic_mentionSGMTdiscussed_in_filing Trusted Computing
topic_mentionSGMTdiscussed_in_filing Blockchain & Crypto
topic_mentionSGMTdiscussed_in_filing Capital Expenditure
topic_mentionSGMTdiscussed_in_filing Regulation
topic_mentionSGMTdiscussed_in_filing Healthcare & Bio
topic_mentionSGMTdiscussed_in_filing Platform & Ecosystem
topic_mentionSGMTdiscussed_in_filing Artificial Intelligence
topic_mentionSGMTdiscussed_in_filing Cybersecurity
topic_mentionSGMTdiscussed_in_filing Trusted Computing
topic_mentionSGMTdiscussed_in_filing Blockchain & Crypto
topic_mentionSGMTdiscussed_in_filing Capital Expenditure
topic_mentionSGMTdiscussed_in_filing Regulation
topic_mentionSGMTdiscussed_in_filing Healthcare & Bio
topic_mentionSGMTdiscussed_in_filing Platform & Ecosystem
topic_mentionSGMTdiscussed_in_filing Artificial Intelligence
topic_mentionSGMTdiscussed_in_filing Cybersecurity
topic_mentionSGMTdiscussed_in_filing Trusted Computing
topic_mentionSGMTdiscussed_in_filing Blockchain & Crypto

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-112025-12-310001104659-26-026140EDGAR107K words
2025-03-122024-12-310001558370-25-002747EDGAR—
2024-03-252023-12-310001558370-24-003812EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-132025-09-300001104659-25-110846EDGAR20K words
2025-08-132025-06-300001558370-25-011301EDGAR—
2025-05-082025-03-310001558370-25-006836EDGAR—
2024-11-142024-09-300001558370-24-015623EDGAR—
2024-08-142024-06-300001558370-24-012136EDGAR—
2024-05-152024-03-310001558370-24-008205EDGAR—
2023-11-132023-09-300001558370-23-018700EDGAR—
2023-08-212023-06-300001104659-23-093910EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-110001104659-26-026146EDGAR7K words
2026-02-020001104659-26-008925EDGAR—
2025-12-180001104659-25-122272EDGAR—
2025-12-170001104659-25-121819EDGAR—
2025-11-130001104659-25-110852EDGAR—
2025-10-230001104659-25-101819EDGAR—
2025-08-220001104659-25-081630EDGAR—
2025-08-140001104659-25-078752EDGAR—
2025-08-130001104659-25-077200EDGAR—
2025-06-100001104659-25-058201EDGAR—

63 total filings indexed. 42 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Company Identity

CIK0001400118
TickerSGMT
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: d17925a2a4d5fc9b37acfe02b23e7602c457e3ae45c6f4c670af0958bd752a19
parent: 557d344142ef3dba237c6bedf1df2deaf1816711fcf2b53ad8ad5292905be7b0
content hash: cd35cd8bc3a2752ba1707ec9d2733fbeec7c6951ab0adfdd95f85bd80529d097
signed: 2026-04-13T04:47:24.861Z
sources: 11 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf